Falk Roeder

Prof. Dr. Falk Roeder

Department of Radiotherapy and Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
+1

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Falk RoederFalk Roeder
Falk Roeder
EME. Meldolesi
E. Meldolesi
SGS. Gerum
S. Gerum
VVVincenzo Valentini
Vincenzo Valentini
CRC. Rödel
C. Rödel
The role of radiation therapy in the treatment of (colo)-rectal cancer has changed dramatically over the past decades. Introduced with the aim of reducing the high rates of local recurrences after conventional surgery, major developments in imaging, surgical technique, systemic therapy and radiation delivery have now created a much more complex environment leading to a more personalized approach. Functional aspects including reduction of acute or late treatment-related side effects, sphincter or even organ-preservation and the unsolved problem of still high distant failure rates have become more important while local recurrence rates can be kept low in the vast majority of patients. This review summarizes the actual role of radiation therapy in different subgroups of patients with rectal cancer, including the current standard approach in different subgroups as well as recent developments focusing on neoadjuvant treatment intensification and/or non-operative treatment approaches aiming at organ-preservation.

1 September 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
Falk RoederFalk Roeder
Falk Roeder
VMVirginia Morillo
Virginia Morillo
LSLadan Saleh-Ebrahimi
Ladan Saleh-Ebrahimi
FCFelipe A. Calvo
Felipe A. Calvo
PPPhilip Poortmans
Philip Poortmans
CACarlos Ferrer Albiach
Carlos Ferrer Albiach

3 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Falk RoederFalk Roeder
Falk Roeder
Radiation therapy (RT) is an integral part of the treatment of adult soft-tissue sarcomas (STS). Although mainly used as perioperative therapy to increase local control in resectable STS with high risk features, it also plays an increasing role in the treatment of non-resectable primary tumors, oligometastatic situations, or for palliation. Modern radiation techniques, like intensity-modulated, image-guided, or stereotactic body RT, as well as special applications like intraoperative RT, brachytherapy, or particle therapy, have widened the therapeutic window allowing either dose escalation with improved efficacy or reduction of side effects with improved functional outcome. This review summarizes the current evidence for RT in adult STS including typical indications, outcomes, side effects, dose and fractionation regimens, and target volume definitions based on tumor localization and risk factors. It covers the different overall treatment approaches including RT either as part of a multimodal treatment strategy or as a sole treatment, namely its use as an adjunct to surgery in resectable STS (perioperative RT), as a primary treatment in non-resectable tumors (definitive RT), as a local treatment modality in oligometastatic disease or as palliative therapy. Due to the known differences in clinical course, general treatment options and, consequently, outcome depending on lesion localization, the main part of perioperative RT is divided into three sections according to body site (extremity/trunk wall, retroperitoneal, and head and neck STS) including the discussion of special applications of radiation techniques specifically amenable to this region. The review of the current evidence is accompanied by a summary on ongoing clinical research pointing at future directions of RT in STS.

1 December 2020 in Journal of Bone Oncology
Verified
Journal Article
Open access
AMAnnika Müller
Annika Müller
MDMartin Dreyling
Martin Dreyling
Falk RoederFalk Roeder
Falk Roeder
ABAndrea Baur-Melnyk
Andrea Baur-Melnyk
TKThomas Knösel
Thomas Knösel
HDHans Roland Dürr
Hans Roland Dürr
Primary lymphoma of bone (PBL) is a rare entity. Due to unspecific clinical signs and equivocal radiographs diagnosis may be delayed. This retrospective report of 109 PBL cases demonstrates typical aspects of the lesion. Treatment and prognostic factors are evaluated. Retrospectively patient records were reviewed. All patients were followed for evidence of local or distant recurrence. Overall survival (OS) was used as clinical outcome. The median age of the 109 patients was 62.8 years. The most common symptoms were pain (76%), swelling (29%), neurologic symptoms and pathological fracture (16% each). Mean duration of symptoms was 8 months (0–197 months). 19% of patients had indolent NHL subtypes, 72% aggressive NHL subtypes and 7% cases Hodgkin disease. Cyclophosphamid, doxorubicin, vincristine and prednisone (CHOP) or CHOP plus rituximab (RCHOP) were given in 88 (81%) of patients. Radiotherapy was delivered in 67 (61%) of cases. 51 (47%) patients received both. Surgical interventions were restricted to cases with complications as fractures. The 5-year OS was 66%. The 5-year OS was 66%. In the subgroup of 78 patients with aggressive NHL subtype there was a highly significant benefit for chemotherapy or chemotherapy and radiation in comparison to no treatment or radiation alone. Raised LDH, age, IPI and ECOG performance were prognostic factors. In multivariate analysis, age and raised LDH levels only kept significance. In our series of primary bone lymphoma, chemotherapy resulted in a better outcome than Radiotherapy alone. Long-term survival is based on the stage of the disease, favoring younger (<60 years) patients with solitary bone lesions, low level of LDH and favourable ECOG performance status and IPI scores.

15 May 2019 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
SGSabine Gerum
Sabine Gerum
AJAlexandra D Jensen
Alexandra D Jensen
Falk RoederFalk Roeder
Falk Roeder
Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review

1 May 2023 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
Falk RoederFalk Roeder
Falk Roeder
AJAlexandra D Jensen
Alexandra D Jensen
KLKatja Lindel
Katja Lindel
MMMatthias Mattke
Matthias Mattke
FWFrank Wolf
Frank Wolf
SGSabine Gerum
Sabine Gerum
Elderly patients represent a growing subgroup of cancer patients for whom the role of radiation therapy is poorly defined. Older patients are still clearly underrepresented in clinical trials, resulting in very limited high-level evidence. Moreover, elderly patients are less likely to receive radiation therapy in similar clinical scenarios compared to younger patients. However, there is no clear evidence for a generally reduced radiation tolerance with increasing age. Modern radiation techniques have clearly reduced acute and late side effects, thus extending the boundaries of the possible regarding treatment intensity in elderly or frail patients. Hypofractionated regimens have further decreased the socioeconomic burden of radiation treatments by reducing the overall treatment time. The current review aims at summarizing the existing data for the use of radiation therapy or chemoradiation in elderly patients focusing on the main cancer types. It provides an overview of treatment tolerability and outcomes with current standard radiation therapy regimens, including possible predictive factors in the elderly population. Strategies for patient selection for standard or tailored radiation therapy approaches based on age, performance score or comorbidity, including the use of prediction tests or geriatric assessments, are discussed. Current and future possibilities for improvements of routine care and creation of high-level evidence in elderly patients receiving radiation therapy are highlighted.